BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles British Journal of Haematology Year : 2021

BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres

Abstract

No abstract available

Domains

Cancer

Dates and versions

inserm-03349131 , version 1 (20-09-2021)

Identifiers

Cite

Hervé Ghesquières, Cécile Dalban, Emmanuelle Nicolas‐virelizier, Fabrice Jardin, Fabien Le Bras, et al.. BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres. British Journal of Haematology, 2021, 192 (3), pp.e94-e98. ⟨10.1111/bjh.17279⟩. ⟨inserm-03349131⟩
34 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More